Elevance Health Inc. (ELV) gains on deep earnings beat
April 23, 202612 min read
Key Takeaway
Elevance Health Inc. (ELV) delivered a strong Q1 2026 beat, with adjusted EPS of $12.58 on revenue of $49.49 billion, and management raised full-year earnings guidance. The quarter was driven by better operating performance, Medicare Advantage improvement, and about $1 per share of nonrecurring investment income, while Medicaid cost pressure and a $935 million CMS accrual still cloud the outlook for investors.
Elevance Health Inc. (ELV) posted a clean headline beat in its latest quarter, then lifted full-year earnings guidance, giving the market a reason to lean positive even as several risk items stayed in view. ELV shares showed modest gains after the report, which fits the tone of the quarter: better numbers, better guidance, but not a full escape from Medicaid cost pressure and the CMS overhang.
Key Takeaways
ELV earnings came in ahead of expectations, with Q1 2026 adjusted EPS of $12.58 and revenue of $49.49B. Management said both operating performance and nonrecurring investment income helped drive the upside.
The most notable segment story was Medicare Advantage improvement, while Medicaid remained the main debate. Management said Medicare is on track for at least a 2% operating margin in 2026, while Medicaid cost actions are showing early progress.
Guidance moved higher. Elevance raised 2026 adjusted diluted EPS guidance to at least $26.75 from the prior floor of $25.50, and management reiterated a path to at least 12% adjusted EPS growth in 2027 off a revised 2026 baseline of $25.75.
Carelon remained a strategic growth engine, although first-quarter operating gain dipped modestly from last year due to lower health plan membership and ongoing investment. Even so, management pointed to strong demand for risk-based and integrated care capabilities.
CEO Gail Boudreaux framed the quarter as proof that execution is improving across the enterprise, while CFO Mark Kaye stressed that favorable claims experience, ACA seasonality, and about $1 per share of nonrecurring investment income all mattered in the quarter.
Analyst reaction was constructive but measured. The Street liked the beat-and-raise setup, yet remained focused on the $935M CMS accrual, Medicaid trend durability, and whether ACA mix benefits in Q1 simply pull costs into the back half of the year.
Financial Performance Breakdown From ELV Earnings
The hard numbers were good. The quality of those numbers is where the real ELV earnings analysis starts.
Elevance reported Q1 2026 operating revenue of $49.5B, up 1.5% year over year and slightly above the prior quarter's $49.75B annualized run rate context. Reported quarterly revenue also topped the market expectation cited in post-earnings coverage at $49.49B. Adjusted diluted EPS reached $12.58, well above recent consensus figures and ahead of the company’s own internal expectations.
That EPS result looks even stronger when set against ELV’s recent surprise history. The company posted $11.97 in Q1 2025, $8.84 in Q2 2025, $6.03 in Q3 2025, $3.33 in Q4 2025, and now $12.58 in Q1 2026. Seasonality matters here, especially in managed care, but the latest number still marks a sharp rebound from the softer second half of 2025.
Margins were mixed, which is typical for a quarter that beats while still carrying visible friction. The consolidated benefit expense ratio was 86.8%. That implies medical costs remained elevated, but still came in modestly better than management had planned. Meanwhile, the adjusted operating expense ratio improved 20 basis points year over year to 10.5%, showing better cost control even as Elevance continued to invest in AI and Carelon capabilities.
In plain English, the company is doing a better job controlling what it can control. That matters in insurance, where a few basis points can change the whole story.
On segment revenue, annual disclosures show the business is still anchored by Health Benefits, with Carelon as the second major engine. For full-year 2025, Health Benefits generated $167.09B and Carelon Services delivered $71.72B, offset by segment eliminations. That mix explains why investors keep watching both insurance underwriting and service-based growth. Health Benefits pays the bills today. Carelon is supposed to widen the moat tomorrow.
Within the quarter, Medicare stood out positively. Management said portfolio repositioning and selective market exits are supporting better performance, and the company remains on track for at least a 2% Medicare operating margin in 2026. Commercial also developed as planned, helped by disciplined pricing. Individual ACA produced a seasonal tailwind because bronze-plan mix pushes more planned costs into the second half.
Medicaid was better than feared, not fully fixed. That distinction matters. Management said early cost actions in behavioral health and specialty pharmacy are helping, but it kept a prudent full-year Medicaid operating margin outlook of about negative 1.75%. So the quarter showed stabilization, not victory.
Two notable line items also shaped the quarter. First, Elevance recorded a $935M accrual tied to a CMS notice on historical risk adjustment data. Second, it booked a $129M business optimization charge. Both were excluded from adjusted earnings. Neither item changes the headline beat, but both remind investors that managed care accounting can look tidy on the surface while carrying real regulatory and restructuring noise underneath.
Cash flow was solid. Operating cash flow reached $4.3B in the quarter, and the company still expects at least $5.5B for the full year, including potential cash payments tied to the CMS matter. Elevance also repurchased 3.7M shares for $1.1B at an average price just above $300, reinforcing that management still sees value in the stock at current levels.
Market Reaction and Analyst Response After the ELV Earnings Call
The immediate market response was positive, but restrained. That fits a report where the company beat, raised, and still left enough open questions to keep enthusiasm on a short leash. The stock was indicated higher after the release, and by the next session ELV traded around $328.20, up 0.03%, with volume above average at 2.63M shares versus a 2.01M average.
That muted next-day move says a lot. Investors did not reject the quarter. They simply did not chase it. In this sector, a beat driven partly by favorable claims and a nonrecurring investment gain will always get a second look.
Analyst sentiment remains broadly supportive. Consensus still sits at Buy, with 26 Buy ratings and 11 Hold ratings. However, price target moves around the print show the Street is balancing better near-term execution against unresolved cost and regulatory risk.
Jefferies trimmed its target to $391 from $395 ahead of the report while keeping Buy. Robert W. Baird cut its target to $317 from $340 and stayed Neutral. Those moves framed the setup before earnings, and the quarter did not fully erase the caution. The beat-and-raise case improved confidence, but the CMS accrual and Medicaid trend debate kept analysts from treating this as a simple rerating story.
Post-earnings commentary centered on four issues. First, ELV earnings clearly beat expectations. Second, the guidance raise to at least $26.75 was real and helpful. Third, the quality of the beat drew scrutiny because about $1 per share came from nonrecurring valuation adjustments in net investment income. Fourth, the $935M CMS accrual remains a live overhang.
That last point matters most for sentiment. A regulatory issue tied to historical risk adjustment data is not the kind of item investors casually wave away. Management says it does not affect the outlook. Analysts, naturally, want proof. Markets have a dry sense of humor about one-time charges. They hear 'nonrecurring' and often wait to see how many times it recurs.
Still, there was enough in the quarter to support the bull case. Medicare improved. Commercial pricing stayed disciplined. ACA membership is tracking ahead of the initial outlook. Carelon demand remains healthy. If those trends hold through the next two quarters, analysts may become more willing to look past the current noise and focus on 2027 growth potential.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Management Commentary Sets the ELV Earnings Narrative
CEO Gail Boudreaux set the strategic tone early. Her message was that Elevance is becoming more coordinated, more data-driven, and more disciplined as healthcare cost pressure rises across the system.
"In the first quarter, our performance exceeded expectations, driven by underlying business strength, along with ACA seasonality and nonrecurring investment income. While it is still early in the year, the trends we are seeing give us increased confidence in the trajectory of the business. That is why we are raising our full year adjusted diluted earnings per share guidance to at least $26.75." — Gail Boudreaux, President and CEO, Earnings Call
That quote matters because it balances confidence with caution. Boudreaux did not pretend the quarter was pure operating leverage. She explicitly acknowledged seasonality and investment income. That tends to help credibility.
"Second, we are embedding and scaling AI across clinical, operational and administrative workflows where it can have direct measurable impact, and we are already seeing tangible results. These capabilities are improving how we engage members and how we manage costs." — Gail Boudreaux, President and CEO, Earnings Call
The AI point is not just executive garnish. For Elevance, AI is being framed as a cost-management and care-coordination tool. If it works, it can improve both medical trend and administrative efficiency. That is the kind of double benefit investors want in managed care.
Boudreaux also made a point to reassure the market on the CMS issue, saying the company is engaging constructively and that the matter does not change its outlook or operating expectations. Strategically, she emphasized Carelon, integrated care, and Medicare repositioning as the main drivers of better consistency.
CFO Mark Kaye handled the financial bridge with more precision. His remarks made clear that the quarter was strong, but not all of the upside should be treated as repeatable.
"Elevance Health reported first quarter adjusted diluted earnings per share of $12.58, which exceeded our expectations. The strength in our operating results reflected favorable claims experience and seasonality in our Individual ACA business. In addition, we recognized approximately $1 per share from nonrecurring valuation adjustments within net investment income." — Mark Kaye, CFO, Earnings Call
That is the key CFO quote because it tells investors exactly how to normalize the quarter. Some upside came from better operations. Some came from timing. Some came from a one-off investment item. Good analysis separates those buckets.
"We are raising our full year 2026 adjusted diluted earnings per share guidance to at least $26.75 based on our first quarter results, and we view the assumptions embedded in our outlook as appropriate and supported by current operating trends." — Mark Kaye, CFO, Earnings Call
Kaye also reiterated that Elevance expects to return to at least 12% adjusted EPS growth in 2027 off a revised 2026 baseline of $25.75. That is an important detail. It suggests management sees 2026 as a reset year and 2027 as the cleaner earnings acceleration story.
Analyst Q and A Highlights From the ELV Earnings Call
The Q and A is where the pleasant script gets tested. Even in the truncated transcript, the pressure points are clear from management’s prepared remarks and the analyst themes that followed.
The first major issue was the quality of the beat. Analysts pressed on how much of the quarter came from favorable claims versus timing versus nonrecurring gains. Management’s answer was effectively that about two-thirds of operating outperformance came from favorable claims experience and cost actions, while about one-third came from ACA seasonality. Then there was the separate $1 per share investment item.
"Medical costs were modestly better than we had assumed in our outlook, reflecting both favorable claims experience and the impact from actions we have taken to manage trend. These collectively contributed approximately 2/3 of our operating outperformance in the quarter. The remaining 1/3 reflected seasonality in our Individual ACA business." — Mark Kaye, CFO, Earnings Call
That exchange matters because analysts were trying to determine what should carry forward. Management defended the underlying improvement, but also conceded that seasonality played a meaningful role. So the market will likely demand confirmation in Q2 and Q3.
The second major issue was Medicaid. Analysts wanted to know whether lower costs in behavioral health and specialty pharmacy represent a durable trend or a temporary pause. Management’s response was careful. It pointed to early evidence of improvement, especially through targeted interventions and predictive analytics, but kept the full-year Medicaid margin outlook conservative.
"In Medicaid, we are seeing early evidence that our actions are lowering costs, particularly in behavioral health and specialty pharmacy. That progress is being driven by more targeted, proactive interventions that allow us to engage earlier, coordinate care more effectively and support members in the most appropriate settings." — Gail Boudreaux, President and CEO, Earnings Call
That answer defended the strategy without overselling the result. It was a sensible response, though not one likely to silence every skeptic. Medicaid remains the part of the story that can still wobble the whole machine.
The third issue was regulatory risk and the CMS notice. Analysts understandably focused on the $935M accrual and whether more downside could emerge. Management’s stance was firm: the company believes its accrual reflects the current best estimate, it stands behind the integrity of its risk adjustment program, and the matter does not alter the operating outlook.
A fourth topic, hinted at by the first analyst question from A.J. Rice of UBS, involved the PBM selling season and likely demand trends tied to integrated medical and pharmacy offerings. That line of questioning fits the broader Street debate. Can Carelon and the integrated platform become a stronger growth and retention lever, especially as employers push harder on total healthcare cost? Management’s prepared remarks suggest yes, pointing to a robust pipeline and early commercial wins.
Taken together, the Q and A reinforced a simple point. Analysts were not disputing that the quarter was good. They were testing how much of it was durable. Management had solid answers, but the burden of proof now shifts to execution over the next few quarters.
Bottom Line
This ELV earnings call gave investors a better setup than the stock had going in. Elevance Health Inc. (ELV) beat, raised guidance, and showed real progress in Medicare, cost discipline, and enterprise execution. However, the market is still waiting for cleaner proof that Medicaid trends are stabilizing and that the CMS issue stays contained.
For now, the stock looks like a managed care name with improving fundamentals and unfinished business. If the next quarter confirms that this was more than timing and one-off help, ELV could have room for further gains from here.
+Did Elevance Health (ELV) beat earnings in Q1 2026?
Yes. Elevance Health reported Q1 2026 adjusted diluted EPS of $12.58 and revenue of $49.49 billion, both ahead of expectations. Management said the upside came from operating performance, favorable claims experience, ACA seasonality, and about $1 per share of nonrecurring investment income.
+Why did ELV stock rise after earnings?
ELV shares gained because the company delivered a clean earnings beat and raised full-year guidance. Investors also reacted positively to improving Medicare Advantage performance and signs that Medicaid cost actions are starting to help.
+What did Elevance Health raise its 2026 EPS guidance to?
Elevance raised 2026 adjusted diluted EPS guidance to at least $26.75, up from the prior floor of $25.50. Management also reiterated a path to at least 12% adjusted EPS growth in 2027 off a revised 2026 baseline of $25.75.
+What are the main risks for Elevance Health after this quarter?
The biggest risks are Medicaid margin pressure and the CMS overhang from a $935 million accrual tied to historical risk adjustment data. Investors are also watching whether the Q1 ACA mix benefit shifts costs into the second half of the year.
Want the full picture on ELV?
Read the analyst-grade research report — charts, grades, and price targets.
